Cargando…
Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine
PURPOSE: Predictive biomarkers for capecitabine benefit in triple-negative breast cancer (TNBC) have been recently proposed using samples from phase III clinical trials, including non-basal phenotype and biomarkers related to angiogenesis, stroma, and capecitabine activation genes. We aimed to valid...
Autores principales: | Asleh, Karama, Lluch, Ana, Goytain, Angela, Barrios, Carlos, Wang, Xue Q., Torrecillas, Laura, Gao, Dongxia, Ruiz-Borrego, Manuel, Leung, Samuel, Bines, José, Guerrero-Zotano, Ángel, García-Sáenz, Jose Ángel, Cejalvo, Juan Miguel, Herranz, Jesus, Torres, Roberto, de la Haba-Rodriguez, Juan, Ayala, Francisco, Gómez, Henry, Rojo, Federico, Nielsen, Torsten O., Martin, Miguel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873250/ https://www.ncbi.nlm.nih.gov/pubmed/36346687 http://dx.doi.org/10.1158/1078-0432.CCR-22-2191 |
Ejemplares similares
-
CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer
por: Guerrero-Zotano, Ángel, et al.
Publicado: (2023) -
Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)
por: Lluch, Ana, et al.
Publicado: (2020) -
82786 Quantification of the Accuracy of Stereotactic Radiosurgery using Surface Guided Imaging with 3D Printed Head Phantoms
por: Bry, Victoria, et al.
Publicado: (2021) -
Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
por: Pascual, Javier, et al.
Publicado: (2023) -
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
por: Schettini, Francesco, et al.
Publicado: (2021)